J R Groothuis
Overview
Explore the profile of J R Groothuis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
857
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Groothuis J
Eur J Clin Microbiol Infect Dis
. 2003 Jun;
22(7):414-7.
PMID: 12827537
Respiratory syncytial virus is an important cause of hospitalization in preterm infants. Palivizumab, a humanized monoclonal antibody against the respiratory syncytial virus fusion protein, is currently the only licensed product...
2.
Simoes E, Groothuis J
Respir Med
. 2002 May;
96 Suppl B:S15-24.
PMID: 11996400
Respiratory syncytial virus (RSV) is a common and highly contagious pathogen that infects nearly all children by the age of 2 years. It is responsible for significant morbidity and mortality...
3.
Groothuis J
Pediatr Infect Dis J
. 2001 Jun;
20(6):628-30.
PMID: 11419509
An Expanded Access Study was conducted to collect additional safety data on palivizumab. Preterm infants with or without bronchopulmonary dysplasia received palivizumab every 30 days during the respiratory syncytial virus...
4.
5.
Meissner H, Groothuis J, Rodriguez W, Welliver R, Hogg G, Gray P, et al.
Antimicrob Agents Chemother
. 1999 May;
43(5):1183-8.
PMID: 10223933
We conducted a multicenter, double-blind, placebo-controlled, randomized trial of a humanized monoclonal antibody against a respiratory syncytial virus (RSV) fusion protein (SB 209763) to evaluate its safety, pharmacokinetics, and fusion...
6.
7.
Simoes E, Sondheimer H, Top Jr F, Meissner H, Welliver R, KRAMER A, et al.
J Pediatr
. 1998 Oct;
133(4):492-9.
PMID: 9787686
Objective: To examine the effectiveness of respiratory syncytial virus immune globulin administered intravenously (RSV-IGIV) in reducing hospitalization for treatment of RSV in children with congenital heart disease (CHD). Methods: Children...
8.
Groothuis J, King S, Hogerman D, Paradiso P, Simoes E
J Infect Dis
. 1998 Feb;
177(2):467-9.
PMID: 9466539
Respiratory syncytial virus (RSV) causes serious respiratory illness in preterm children with bronchopulmonary dysplasia. In a prospective randomized placebo-controlled trial, 21 children received one dose of PFP-2 (purified fusion [F]...
9.
Rodriguez W, Gruber W, Groothuis J, Simoes E, Rosas A, Lepow M, et al.
Pediatrics
. 1997 Dec;
100(6):937-42.
PMID: 9374560
Objective: To evaluate the efficacy of high titer respiratory syncytial virus (RSV) immune globulin (RSVIG) in the treatment of previously healthy children hospitalized with proven RSV lower tract infection (LRI)....
10.
Meissner H, Groothuis J
Pediatrics
. 1997 Aug;
100(2 Pt 1):260-3.
PMID: 9240809
No abstract available.